What was recalled
This page synthesizes the regulatory and clinical framework around vitamin D supplementation in commercial pet food. Vitamin D functions as a steroid hormone after dual hydroxylation (25-hydroxyvitamin D in liver, 1,25-dihydroxyvitamin D in kidney). The active hormone regulates intestinal calcium and phosphorus absorption, renal mineral reabsorption, and bone remodeling. Emerging research extends vitamin D function to immune regulation, cancer prevention (limited evidence in companion animals), and cardiovascular function. Dietary vitamin D sources fall into two categories. Vitamin D3 (cholecalciferol) is structurally identical to the endogenously-synthesized form (UV-mediated conversion of 7-dehydrocholesterol in skin). Commercial pet food sources cholecalciferol from lanolin extraction (sheep wool grease yields 7-dehydrocholesterol, UV photosynthesis converts this to cholecalciferol). The process is shared with human vitamin D supplement manufacturing.
Vitamin D2 (ergocalciferol) is the plant-source form derived from ergosterol UV photosynthesis. Commercial sources include UV-treated Agaricus bisporus (button mushrooms), Cordyceps, and yeast-derived ergosterol. Carnivore species absorb and convert D2 inefficiently: dogs convert at approximately 10-30% of D3 efficiency, cats at approximately 5-20%. Human and herbivore conversion is much more efficient. Vegan and vegetarian pet food brands face a structural sourcing problem: D2 substitution delivers inadequate biological vitamin D activity for dogs and cats. Lanolin-derived D3 remains the bioavailable option but is animal-derived (sheep wool grease processing).
Why it was recalled
The structural controversy has three layers. Layer one — D2 substitution in vegan pet food: the vegan and vegetarian pet food category has grown substantially, driven by owner ethical preferences and perceived environmental sustainability. Vegan formulations face a vitamin D sourcing problem: cholecalciferol is lanolin-derived (animal source); ergocalciferol substitution is poorly utilized by carnivore species. Some vegan brands disclose D2 substitution; others use lanolin-derived D3 while marketing as "plant-based" without distinguishing the supplement source. The labeling transparency gap is structural across the vegan-pet-food category. Vegan-vegetarian pet food adequacy covers the broader framework.
Layer two — premix-mixing toxicity: vitamin D has the narrowest therapeutic window of any pet food fat-soluble vitamin. AAFCO canine maximum is 3,000 IU/kg dry matter; toxic doses begin at 5-10x AAFCO maximum with chronic exposure. Premix-mixing errors are documented across multiple decades of pet food recall history. The 2018-2019 multi-brand vitamin D toxicity recall involved Hill's Prescription Diet, Sunshine Mills, Natural Life, and others; affected lots delivered 70-700x AAFCO maximum, producing clinical hypercalcemia, renal injury, and death in dogs across the United States. Subsequent premix supplier mixing error framework reforms (lot-level traceability, finished-product assay) have reduced but not eliminated recurrence risk.
Layer three — AAFCO 2018 maximum reduction: AAFCO reduced canine vitamin D maximum from 5,000 IU/kg dry matter to 3,000 IU/kg in 2018, responding to accumulated case-series data on chronic vitamin D toxicity at sub-recall doses. The update did not address the wider veterinary concern that chronic intake near the maximum may contribute to subclinical hypercalcemia and renal microcalcification, particularly in senior dogs with reduced renal reserve. Some veterinary nutritionists advocate further maximum reduction to 1,500-2,000 IU/kg for adult maintenance; AAFCO has not adopted this position.
Health risks for your pet
The clinical risk profile from vitamin D in commercial pet food is dominated by toxicity rather than deficiency. Acute vitamin D toxicity produces hypercalcemia, hyperphosphatemia, polyuria-polydipsia, vomiting, lethargy, and acute kidney injury with mineralization. The 2018-2019 recall provided extensive clinical documentation; affected dogs frequently required hospitalization, fluid therapy, calcium-binding therapy, and prolonged renal management. Mortality in confirmed cases exceeded 10%. Chronic subclinical vitamin D excess from sustained intake near AAFCO maximum may contribute to renal microcalcification and accelerated chronic kidney disease progression in senior dogs and cats, though direct causal evidence is limited.
Vitamin D deficiency from commercial pet food is uncommon when D3 (cholecalciferol) supplementation meets AAFCO minimum. The deficiency concern arises in vegan and vegetarian formulations using D2 substitution, in home-prepared diets without vitamin D supplementation, and in raw diets when liver inclusion is inadequate. Clinical deficiency produces hypocalcemia, hypophosphatemia, rickets in growing animals, and osteomalacia in adults. Subclinical deficiency contributes to immune dysfunction and may affect emerging-research-stage outcomes (cancer prevention, cardiovascular function) where vitamin D status is implicated. The lanolin-source ethical concern for vegan pet food owners is real but does not change the biological inadequacy of D2 substitution in carnivore species.
What to do if you bought affected product
Pet owners can manage vitamin D concerns through several practical approaches: (1) select diets using D3 (cholecalciferol) supplementation rather than D2 (ergocalciferol); ingredient deck inspection reveals the form; vegan brands using D2 substitution are providing inadequate vitamin D activity for dogs and cats; (2) avoid the highest end of the AAFCO vitamin D range for senior pets with reduced renal reserve; concentrations in the lower-middle of the AAFCO range (1,000-2,000 IU/kg dry matter for dogs) reduce chronic-excess risk while meeting adequacy; (3) monitor recall notifications from the FDA pet food recall database; vitamin D toxicity recalls have recurred and may recur again; (4) request finished-product vitamin D assay from brand customer service; brands that perform finished-product vitamin D quality control beyond batch-level premix verification offer better protection against premix-mixing errors; (5) do not add vitamin D supplements to commercial pet food unless veterinary-directed for diagnosed deficiency; total vitamin D intake from commercial diet plus over-the-counter supplementation can rapidly exceed safety thresholds; (6) vegan-pet-food owners with cats should reconsider — the obligate carnivore status of cats produces multiple structural inadequacy concerns (taurine, arachidonic acid, vitamin D) beyond vitamin D alone; the ACVN consensus position is that cats should not be fed vegan diets without rigorous formulation oversight.
How this affects KibbleIQ’s grade
The KibbleIQ rubric v15 does not currently differentiate vitamin D source form per our published methodology, since D3 (cholecalciferol) supplementation is essentially universal in mainstream commercial pet food and the brand-level transparency on dose and finished-product assay is limited. Future rubric extension under consideration: brands publishing finished-product vitamin D concentration with lot-level assay would receive favorable scoring weight; vegan formulations using D2 (ergocalciferol) substitution would receive scoring penalty for delivering inadequate biological vitamin D activity to carnivore species. Pet owners with senior pets or renal-compromised pets should prioritize lower-end AAFCO range vitamin D concentrations and avoid over-the-counter supplementation without veterinary direction. The premix-mixing toxicity risk class is the dominant practical concern; the 2018-2019 multi-brand recall is the reference event.